Antibodies News and Research

RSS

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term.

28 Sep 2021

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

Hamilton Company and Rhinostics are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows.

From Hamilton Process Analytics 28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Researchers from the University of Oxford and the University of Warwick have collaborated to develop a method to better understand and evaluate these pleiomorphisms.

28 Sep 2021

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

It has been demonstrated in recent studies that there is a significant breadth of emerging autoreactivity associated with severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. More specifically, researchers from Emory University have identified a relaxation of peripheral tolerance within early antibody secretion cells that arise in individuals infected with SARS-CoV-2, as important drivers of those responses.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

A new study explores the real-world efficacy of monoclonal antibodies against COVID-19 in averting severe disease.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new study describes a new variant that possesses a novel combination of various concerning mutations at the spike region.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

New research has found that children and youth may be at low risk of severe acute COVID-19, according to a study conducted during the first half of the pandemic and published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210053.

27 Sep 2021

mRNA COVID vaccines prove effective in the elderly

Coronavirus disease 2019 (COVID-19) proved extremely difficult to control once it entered a country – while there were a few success stories such as New Zealand, most countries ended up resorting to lengthy and economically painful lockdowns, among other restriction measures.

27 Sep 2021

Antibodies News and Research

Classic antidepressants show potential to enhance modern cancer treatments

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

COVID Moonshot receives key funding to accelerate drug discovery efforts

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

mRNA COVID vaccines prove effective in the elderly

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo